CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-190

Approval Letter(s)

Food and Drug Administration
Rockville MD 20857

DEC 20 2000

NDA 21-190

Bristol-Meyers Squibb Company
Attention: Michael S. Eison, Ph.D.
Director, Regulatory Science
5 Research Parkway
Wallingford, CT 06492

Dear Dr. Eison:

Please refer to your new drug application (NDA) dated September 23, 1999, received September 24, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for BuSpar (buspirone hydrochloride) Capsules.

We acknowledge receipt of your submissions dated October 20 and November 9, 2000. Your submission of October 20, 2000 constituted a complete response to our July 24, 2000 action letter.

This new drug application provides for a capsule dosage form of BuSpar (buspirone hydrochloride) for the management of anxiety disorders.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert) dated November 9, 2000, as agreed upon during a December 15, 2000, telephone conversation between Ms. Anna Marie Homonnay, Regulatory Project Manager of this Division, and Dr. Michael Eison of Bristol-Myers Squibb Regulatory Affairs Depart. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999). For administrative purposes, this submission should be designated "FPL for approved NDA 21-190." Approval of this submission by FDA is not required before the labeling is used.

POST APPROVAL ISSUES

We refer to our July 24, 2000, Approvable letter in which we requested information about the relationship of dosing to food intake in the original effectiveness trials for the tablet. We still await your response to this issue.

Please be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have fulfilled the pediatric study requirement at this time.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you should have any questions, please call Ms. Anna Marie Homonnay, Regulatory Project Manager, at (301) 594-5535.

Sincerely,

/S/

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-190

Approvable Letter (S)

NDA 21-190

JUL 24 2000

Bristol-Myers Squibb Company
Attention: Jay Gunther, Ph.D.
Director, Worldwide Regulatory Affairs
5 Research Parkway
Wallingford, CT 06492

Dear Dr. Gunther:

Please refer to your new drug application (NDA) dated September 23, 1999, received September 24, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for BuSpar® (buspirone hydrochloride) Capsules, 5 mg, 7.5 mg, 10 mg, and 15 mg.

This NDA provides for a new capsule formulation of BuSpar® (buspirone hydrochloride).

We acknowledge receipt of your amendments dated May 23, 2000(revised draft labeling), and June 8, 2000.

The User Fee goal date for this application is July 24, 2000.

We have completed the review of this application, as submitted with draft labeling, and it is approvable. Before this application may be approved, however, it will be necessary for you to respond to the following:

Labeling Issues

The attachment to this letter is our labeling proposal for Buspar® Capsules. It also incorporates labeling changes from two recent labeling supplements, S-037 and S-039, for NDA 18-731, the tablet dosage form.

While we have proposed a number of changes to the draft labeling you submitted, we wish to draw particular attention to our request, embedded in the body of the label, to add language in the Dosage and Administration section describing the effect of food on buspirone kinetics, and to provide the prescriber with guidance about how this interaction should affect advice to patients. In this regard, we would be interested in information (not necessarily to be included in labeling) about the relationship of dosing

to meals in the controlled trials that established effectiveness.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

If you should have any questions, please contact Anna Marie Homonnay-Weikel, R.Ph., Regulatory Project Manager, at (301) 594-5535.

Sincerely yours,

/s/ 7/24/03

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

attachment

cc:
Archival NDA 21-190
HFD-120/Div. Files
HFD-120/Katz
HFD-120/Laughren/7.20.00
HFD-120/Andreason
HFD-120/Seevers/7.20.00/Rocca
HFD-860/Baweja/7.20.00/Zhao/7.20.00
HFD-120/Homonnay
HFD-002/ORM
HFD-101/ADRA
HFD-95/DDMS
HFD-40/DDMAC (with labeling)
DISTRICT OFFICE

Drafted: ahw/7.19.00
final: ahw/7.20.00
revised: rk/7.24.00
final: ahw/7.24.00

APPROVABLE (AE)

18 pages redacted from this section of the approval package consisted of draft labeling